These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20470225)

  • 1. Retention of immunogenicity produced by mucin 1 peptides with glycosylation site substitutions.
    Wright SE; Quinlin IS; Rewers-Felkins KA; Dombrowski KE; Phillips CA
    Immunopharmacol Immunotoxicol; 2010 Dec; 32(4):647-55. PubMed ID: 20470225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM; Vlad A; Finn OJ
    Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site.
    Wright SE; Kilinski L; Talib S; Lowe KE; Burnside JS; Wu JY; Dolby N; Dombrowski KE; Lebkowski JS; Philip R
    J Immunother; 2000 Jan; 23(1):2-10. PubMed ID: 10687132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.
    Apostolopoulos V; Karanikas V; Haurum JS; McKenzie IF
    J Immunol; 1997 Dec; 159(11):5211-8. PubMed ID: 9548459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC-restricted presentation of a single repeat of MUC1 mucin.
    Orr MK; Burnside JS; Phillips CA; Philip R; Dombrowski KE; Wright SE
    Immunol Invest; 2007; 36(3):271-83. PubMed ID: 17558710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells.
    Hiltbold EM; Alter MD; Ciborowski P; Finn OJ
    Cell Immunol; 1999 Jun; 194(2):143-9. PubMed ID: 10383817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
    Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
    Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.
    Noto H; Takahashi T; Makiguchi Y; Hayashi T; Hinoda Y; Imai K
    Int Immunol; 1997 May; 9(5):791-8. PubMed ID: 9184925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of MUC1-stimulated mononuclear cells using optimized conditions.
    Wright SE; Khaznadar R; Wang Z; Quinlin IS; Rewers-Felkins KA; Phillips CA; Patel S
    Scand J Immunol; 2008 Jan; 67(1):24-9. PubMed ID: 18021186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy.
    Karanikas V; Lodding J; Maino VC; McKenzie IF
    Clin Cancer Res; 2000 Mar; 6(3):829-37. PubMed ID: 10741704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.
    Wright SE; Rewers-Felkins KA; Quinlin IS; Fogler WE; Phillips CA; Townsend M; Robinson W; Philip R
    Immunol Invest; 2008; 37(3):215-25. PubMed ID: 18389441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
    Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T lymphocytes specific for the synthetic VEINCTR peptide, a sequence found within the Fas molecule and env gp120 in the blood of HIV-1 seropositive individuals.
    Moukrim Z; Achour A
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):439-44. PubMed ID: 7580839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts.
    Nishimori I; Perini F; Mountjoy KP; Sanderson SD; Johnson N; Cerny RL; Gross ML; Fontenot JD; Hollingsworth MA
    Cancer Res; 1994 Jul; 54(14):3738-44. PubMed ID: 8033093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.
    Heuser C; Ganser M; Hombach A; Brand H; Denton G; Hanisch FG; Abken H
    Br J Cancer; 2003 Sep; 89(6):1130-9. PubMed ID: 12966437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.